This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in respiratory rate
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in oxygenation saturation
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in blood pressure
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in heart rate
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in body temperature
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in cardiac rate
Timeframe: over 6 sessions from baseline up to 3 weeks
Change in cardiac rhythm
Timeframe: over 6 sessions from baseline up to 3 weeks